Frontiers in Pharmacology (June 2026): Machine-Learning Model Identifies Novel Antimicrobial Peptides Against Pseudomonas aeruginosa Using 124 Experimentally Validated Sequences as External Validation Set
A research team published in Frontiers in Pharmacology in June 2026 a machine-learning pipeline for discovering antimicrobial peptides active against Pseudomonas aeruginosa, one of the WHO's top-priority gram-negative pathogens for new antibiotic development. The model was externally validated using 124 experimentally confirmed AMPs from recent publications. Pseudomonas aeruginosa is a leading cause of ventilator-associated pneumonia and bloodstream infection in immunocompromised patients, and the rise of carbapenem-resistant strains has narrowed remaining treatment options to colistin and ceftolozane-tazobactam. The paper sits in a broader 2026 ML-AMP wave that also includes 'Advances in the Application of Deep Learning for Antimicrobial Peptide Screening' (Agricultural Science and Food Processing) and an arxiv preprint on multilabel AMP classification benchmarks. AMP discovery is one of the few peptide-drug verticals advancing in parallel to GLP-1 headlines, with no commercial obesity-driven distortion of academic publication pipelines.